|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZMAT5 |
Gene summary for ZMAT5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZMAT5 | Gene ID | 55954 |
| Gene name | zinc finger matrin-type 5 | |
| Gene Alias | SNRNP20 | |
| Cytomap | 22q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R1I1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55954 | ZMAT5 | LZE4T | Human | Esophagus | ESCC | 5.31e-05 | 1.70e-01 | 0.0811 |
| 55954 | ZMAT5 | LZE7T | Human | Esophagus | ESCC | 1.47e-02 | 1.79e-01 | 0.0667 |
| 55954 | ZMAT5 | LZE8T | Human | Esophagus | ESCC | 7.66e-03 | 1.26e-01 | 0.067 |
| 55954 | ZMAT5 | LZE20T | Human | Esophagus | ESCC | 3.12e-02 | 1.12e-01 | 0.0662 |
| 55954 | ZMAT5 | LZE22T | Human | Esophagus | ESCC | 2.49e-03 | 2.28e-01 | 0.068 |
| 55954 | ZMAT5 | LZE24T | Human | Esophagus | ESCC | 2.73e-10 | 3.57e-01 | 0.0596 |
| 55954 | ZMAT5 | LZE6T | Human | Esophagus | ESCC | 3.67e-02 | 2.88e-01 | 0.0845 |
| 55954 | ZMAT5 | P2T-E | Human | Esophagus | ESCC | 6.03e-16 | 2.59e-01 | 0.1177 |
| 55954 | ZMAT5 | P4T-E | Human | Esophagus | ESCC | 3.58e-16 | 3.85e-01 | 0.1323 |
| 55954 | ZMAT5 | P5T-E | Human | Esophagus | ESCC | 2.34e-10 | 1.88e-01 | 0.1327 |
| 55954 | ZMAT5 | P8T-E | Human | Esophagus | ESCC | 3.87e-13 | 2.88e-01 | 0.0889 |
| 55954 | ZMAT5 | P9T-E | Human | Esophagus | ESCC | 6.61e-11 | 3.38e-01 | 0.1131 |
| 55954 | ZMAT5 | P10T-E | Human | Esophagus | ESCC | 3.59e-16 | 2.62e-01 | 0.116 |
| 55954 | ZMAT5 | P11T-E | Human | Esophagus | ESCC | 3.65e-04 | 2.70e-01 | 0.1426 |
| 55954 | ZMAT5 | P12T-E | Human | Esophagus | ESCC | 2.59e-25 | 4.49e-01 | 0.1122 |
| 55954 | ZMAT5 | P15T-E | Human | Esophagus | ESCC | 7.54e-14 | 3.91e-01 | 0.1149 |
| 55954 | ZMAT5 | P16T-E | Human | Esophagus | ESCC | 2.83e-23 | 4.17e-01 | 0.1153 |
| 55954 | ZMAT5 | P17T-E | Human | Esophagus | ESCC | 1.32e-05 | 2.77e-01 | 0.1278 |
| 55954 | ZMAT5 | P19T-E | Human | Esophagus | ESCC | 2.27e-05 | 5.96e-01 | 0.1662 |
| 55954 | ZMAT5 | P20T-E | Human | Esophagus | ESCC | 6.71e-09 | 3.27e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZMAT5 | SNV | Missense_Mutation | c.257G>T | p.Ser86Ile | p.S86I | Q9UDW3 | protein_coding | tolerated(0.1) | benign(0.054) | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ZMAT5 | SNV | Missense_Mutation | rs760168004 | c.460N>T | p.Arg154Trp | p.R154W | Q9UDW3 | protein_coding | deleterious(0.05) | possibly_damaging(0.548) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZMAT5 | SNV | Missense_Mutation | c.100N>C | p.Lys34Gln | p.K34Q | Q9UDW3 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZMAT5 | SNV | Missense_Mutation | rs201945154 | c.31G>A | p.Asp11Asn | p.D11N | Q9UDW3 | protein_coding | deleterious(0.04) | benign(0.109) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZMAT5 | SNV | Missense_Mutation | rs766708114 | c.62N>A | p.Arg21His | p.R21H | Q9UDW3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZMAT5 | SNV | Missense_Mutation | novel | c.199N>A | p.Asp67Asn | p.D67N | Q9UDW3 | protein_coding | tolerated(0.09) | possibly_damaging(0.793) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| ZMAT5 | SNV | Missense_Mutation | novel | c.149N>G | p.Asp50Gly | p.D50G | Q9UDW3 | protein_coding | deleterious(0.01) | benign(0.202) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| ZMAT5 | SNV | Missense_Mutation | novel | c.170N>A | p.Cys57Tyr | p.C57Y | Q9UDW3 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZMAT5 | SNV | Missense_Mutation | novel | c.104A>C | p.Lys35Thr | p.K35T | Q9UDW3 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZMAT5 | SNV | Missense_Mutation | novel | c.507N>T | p.Trp169Cys | p.W169C | Q9UDW3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-PG-A915-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |